NeoGenomics, Inc. (NASDAQ:NEO) Stake Increased by Brown Advisory Inc.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Destiny Wealth Partners LLC acquired a new position in shares of NeoGenomics in the third quarter worth $65,000. Archer Investment Corp grew its position in shares of NeoGenomics by 37.1% in the third quarter. Archer Investment Corp now owns 1,350 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 365 shares during the last quarter. James Investment Research Inc. grew its position in shares of NeoGenomics by 47.5% in the third quarter. James Investment Research Inc. now owns 1,550 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 499 shares during the last quarter. Lindbrook Capital LLC bought a new stake in shares of NeoGenomics in the fourth quarter valued at about $84,000. Finally, Andrew Hill Investment Advisors Inc. bought a new stake in shares of NeoGenomics in the fourth quarter valued at about $88,000. Institutional investors own 97.04% of the company’s stock.
Shares of NeoGenomics stock opened at $12.49 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.81 and a quick ratio of 7.54. The company’s fifty day simple moving average is $19.89 and its two-hundred day simple moving average is $32.28. NeoGenomics, Inc. has a 12-month low of $11.00 and a 12-month high of $54.74.
NeoGenomics (NASDAQ:NEO – Get Rating) last announced its quarterly earnings data on Wednesday, February 23rd. The medical research company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. The company had revenue of $125.73 million for the quarter, compared to the consensus estimate of $125.77 million. NeoGenomics had a negative net margin of 1.72% and a negative return on equity of 4.17%. NeoGenomics’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 EPS. On average, equities analysts expect that NeoGenomics, Inc. will post -0.66 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on the stock. Stephens cut shares of NeoGenomics from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $34.00 to $16.00 in a research note on Tuesday. Craig Hallum lowered their price target on shares of NeoGenomics from $46.00 to $30.00 in a report on Thursday, February 24th. Cowen lowered their target price on shares of NeoGenomics from $42.00 to $24.00 and set an “outperform” rating for the company in a report on Tuesday. Needham & Company LLC cut their price objective on shares of NeoGenomics from $29.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, StockNews.com raised shares of NeoGenomics to a “sell” rating in a research report on Monday, February 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, NeoGenomics presently has an average rating of “Buy” and an average price target of $25.36.
In related news, CFO William Bonello sold 3,209 shares of the firm’s stock in a transaction on Monday, March 7th. The stock was sold at an average price of $18.29, for a total value of $58,692.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.70% of the company’s stock.
NeoGenomics Company Profile (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Featured Stories
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- Ralph Lauren Stock Has Made its Line in the Sand
- 3 Beat Up Large Caps With Bullish Chart Patterns
- Big Five Sporting Goods Stock is a Big Bargain Here
- Solo Brands Is So Low It’s Almost Time To Buy It
- It’s “Game On!” For Academy Sports + Outdoors
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Get Rating).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source